http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP982597-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-39 |
| filingDate | 1998-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3fc2bc59abee57f4abb02a86f7dae83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3d9304ca5022c7b14661542bdddd863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7377ba5a16d43f9355ece44b97a7c42e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89c84ba344b711cb990f0f7441edbbe6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbdbd504da789038f25d9e18de0651b4 |
| publicationDate | 1999-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EC-SP982597-A |
| titleOfInvention | DERIVATIVES OF 5H-TIAZOLO (3,2, a) PIRIMIDINE |
| abstract | The invention relates to compounds of the general formula (graph), wherein R1 is hydrogen, lower alkyl, phenyl or benzyl, R2 is lower alkyl, lower alkoxy, -O (CH2) Nn (R13) (R14), - ( CH2) Nn (R13) (R14) or -N (R15) - (CH2) Nn (R13) (R14), R3-R12 means hydrogen, halogen, trifluoromethyl, lower alkyl, cycloalkyl, lower alkoxy, hydroxyl, nitro, cyano , -N (R13) 2, phenyl, phenyloxy, benzyl or benzyloxy, or R6 and R7 together signify a benzene ring, R13-R15 signify hydrogen, lower alkyl or cycloalkyl and n signify 1-5, as well as their pharmaceutically acceptable salts. These compounds are appropriate for the control or prevention of acute and / or chronic neurological disorders, such as limited brain function caused by bypass or transplant operations, poor blood flow to the brain, spinal cord injury, head injury, hypoxia caused by pregnancy. , cardiac arrest and hypoglycemia, Alzheimer's disease, Huntington's chorea ALS, dementia caused by AIDS, eye injuries, retinopathy, cognitive diseases, idiopathic parkinsonism or parkinsonism caused by medications, as well as conditions that lead to glutamate-deficient functions, such as, for example, muscle spasms, seizures, migraine, urinary incontinence, nicotine addiction, psychosis, opiate addiction, anxiety, vomiting, chronic pain, diskinesia, and depression. |
| priorityDate | 1998-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.